Cesca Therapeutics (NASDAQ:KOOL) issued its earnings results on Tuesday. The biotechnology company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.13, Bloomberg Earnings reports. The business had revenue of $4.31 million for the quarter, compared to analysts’ expectations of $3.40 million. Cesca Therapeutics had a negative return on equity of 51.45% and a negative net margin of 355.50%.
Shares of Cesca Therapeutics stock traded down $0.31 on Wednesday, hitting $2.69. 509 shares of the company were exchanged, compared to its average volume of 66,457. The stock has a market cap of $7.90 million, a PE ratio of -0.78 and a beta of 1.00. The stock’s 50-day moving average is $3.07. Cesca Therapeutics has a 1-year low of $2.10 and a 1-year high of $5.25. The company has a quick ratio of 0.81, a current ratio of 1.58 and a debt-to-equity ratio of 0.54.
KOOL has been the topic of several recent research reports. ValuEngine upgraded Cesca Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. HC Wainwright restated a “buy” rating and set a $6.50 target price (up from $1.00) on shares of Cesca Therapeutics in a report on Wednesday.
About Cesca Therapeutics
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.
Featured Story: Fundamental Analysis and Individual Investors
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.